International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ..
PURPOSE: The objectives of the International epidemiology databases to evaluate AIDS (IeDEA) are to (i) evaluate the delivery of combination antiretroviral therapy (ART) in children, adolescents and adults in sub-Saharan Africa, (ii) to describe ART regimen effectiveness, durability and tolerability, (iii) to examine HIV-related comorbidities and coinfections and (iv) to examine the pregnancy-related and HIV-related outcomes of women on ART and their infants exposed to HIV or ART in utero or via breast milk.
PARTICIPANTS: IeDEA is organised in four regions (Central, East, Southern and West Africa), with 240 treatment and care sites, six data centres at African, European and US universities, and almost 1.4 million children, adolescents and adult people living with HIV (PLWHIV) enrolled.
FINDINGS TO DATE: The data include socio-demographic characteristics, clinical outcomes, opportunistic events, treatment regimens, clinic visits and laboratory measurements. They have been used to analyse outcomes in PLWHIV-1 or PLWHIV-2 who initiate ART, including determinants of mortality, of switching to second-line and third-line ART, drug resistance, loss to follow-up and the immunological and virological response to different ART regimens. Programme-level estimates of mortality have been corrected for loss to follow-up. We examined the impact of coinfection with hepatitis B and C, and the epidemiology of different cancers and of (multidrug resistant) tuberculosis, renal disease and of mental illness. The adoption of 'Treat All', making ART available to all PLWHIV regardless of CD4+ cell count or clinical stage was another important research topic.
FUTURE PLANS: IeDEA has formulated several research priorities for the 'Treat All' era in sub-Saharan Africa. It recently obtained funding to set up sentinel sites where additional data are prospectively collected on cardiometabolic risks factors as well as mental health and liver diseases, and is planning to create a drug resistance database.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
BMJ open - 10(2020), 5 vom: 15. Mai, Seite e035246 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chammartin, Frédérique [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Epidemiology |
|---|
| Anmerkungen: |
Date Completed 19.04.2021 Date Revised 31.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2019-035246 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309975026 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309975026 | ||
| 003 | DE-627 | ||
| 005 | 20240331232117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2019-035246 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM309975026 | ||
| 035 | |a (NLM)32414825 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chammartin, Frédérique |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019 |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2021 | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. | ||
| 520 | |a PURPOSE: The objectives of the International epidemiology databases to evaluate AIDS (IeDEA) are to (i) evaluate the delivery of combination antiretroviral therapy (ART) in children, adolescents and adults in sub-Saharan Africa, (ii) to describe ART regimen effectiveness, durability and tolerability, (iii) to examine HIV-related comorbidities and coinfections and (iv) to examine the pregnancy-related and HIV-related outcomes of women on ART and their infants exposed to HIV or ART in utero or via breast milk | ||
| 520 | |a PARTICIPANTS: IeDEA is organised in four regions (Central, East, Southern and West Africa), with 240 treatment and care sites, six data centres at African, European and US universities, and almost 1.4 million children, adolescents and adult people living with HIV (PLWHIV) enrolled | ||
| 520 | |a FINDINGS TO DATE: The data include socio-demographic characteristics, clinical outcomes, opportunistic events, treatment regimens, clinic visits and laboratory measurements. They have been used to analyse outcomes in PLWHIV-1 or PLWHIV-2 who initiate ART, including determinants of mortality, of switching to second-line and third-line ART, drug resistance, loss to follow-up and the immunological and virological response to different ART regimens. Programme-level estimates of mortality have been corrected for loss to follow-up. We examined the impact of coinfection with hepatitis B and C, and the epidemiology of different cancers and of (multidrug resistant) tuberculosis, renal disease and of mental illness. The adoption of 'Treat All', making ART available to all PLWHIV regardless of CD4+ cell count or clinical stage was another important research topic | ||
| 520 | |a FUTURE PLANS: IeDEA has formulated several research priorities for the 'Treat All' era in sub-Saharan Africa. It recently obtained funding to set up sentinel sites where additional data are prospectively collected on cardiometabolic risks factors as well as mental health and liver diseases, and is planning to create a drug resistance database | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV & AIDS | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a infectious diseases | |
| 650 | 4 | |a tuberculosis | |
| 700 | 1 | |a Dao Ostinelli, Cam Ha |e verfasserin |4 aut | |
| 700 | 1 | |a Anastos, Kathryn |e verfasserin |4 aut | |
| 700 | 1 | |a Jaquet, Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Brazier, Ellen |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Dabis, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Davies, Mary-Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Duda, Stephany N |e verfasserin |4 aut | |
| 700 | 1 | |a Malateste, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Nash, Denis |e verfasserin |4 aut | |
| 700 | 1 | |a Wools-Kaloustian, Kara |e verfasserin |4 aut | |
| 700 | 1 | |a von Groote, Per M |e verfasserin |4 aut | |
| 700 | 1 | |a Egger, Matthias |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2011 |g 10(2020), 5 vom: 15. Mai, Seite e035246 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:5 |g day:15 |g month:05 |g pages:e035246 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2019-035246 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 5 |b 15 |c 05 |h e035246 | ||